Vital Technologies

Company Overview

Snapshot

Founded in November 2013 by Amir Barzilay, Vital Technologies operates with 1–10 employees. The company has raised $8M across one funding round from SIBF VC. In September 2019, Vital Technologies secured $8M in funding.

Business overview

Vital Technologies specializes in developing and producing patented microencapsulated GRAS natural actives and commercial performance-enhancing formulation products. These products are designed for seamless integration into commercially available food and beverage items. Utilizing microencapsulated particles under 250 microns, the company's solutions offer fast-acting recovery and an enhanced consumption experience, even with high-dose ingredients. Its proprietary Nutrient Transfer Technology (NT2) pharma-class micro-encapsulation platform supports various natural actives, including nootropics, adaptogens, botanicals, amino acids, electrolytes, and vitamins, by enabling complete taste isolation, active protection, and sophisticated triggered release profiles. The company operates in the Health Tech & Life Sciences sector, with a focus on pharmaceuticals, nutrition, and food and beverage industries.

Strategic signal

In November 2019, Vital Technologies garnered media attention for its 'recovery drink' CUUR, which was highlighted in a Daily Mail article claiming it could alleviate hangovers. This media coverage indicates a strategic focus on consumer-facing products and market validation through popular press, signaling potential for broader market adoption and brand recognition in the wellness and functional beverage space.

Company Intelligence Q&A

What is Vital Technologies' primary business?

Vital Technologies develops and produces patented microencapsulated GRAS natural actives and commercial performance-enhancing formulation products for integration into food and beverage products.

When was Vital Technologies founded?

Vital Technologies was founded in November 2013.

What is the company's core technology?

Vital Technologies utilizes its patented Nutrient Transfer Technology (NT2) pharma-class micro-encapsulation platform to enhance natural actives by providing taste isolation, active protection, and triggered release profiles.

What was a significant funding event for Vital Technologies?

In September 2019, Vital Technologies raised $8M in funding from SIBF VC, an Israeli venture capital firm.

What is the status of Vital Technologies?

Vital Technologies is Non Active and ceased to operate in April 2026.